Vivani Medical VANI Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $18.3M+1.0% | $18.13M+1.8% | $17.8M+1.8% | $17.48M+7.7% | $16.24M+3.1% | ||
| $9.52M+0.9% | $9.43M+0.2% | $9.41M+1.1% | $9.31M+6.1% | $8.77M-1.8% | ||
| $27.81M+0.9% | $27.55M+1.3% | $27.2M+1.6% | $26.79M+7.1% | $25.01M+1.3% | ||
| $27.81M+0.9% | $27.55M+1.3% | $27.2M+1.6% | $26.79M+7.1% | $25.01M+1.3% | ||
| -$27.81M-0.9% | -$27.55M-1.3% | -$27.2M-1.6% | -$26.79M-7.1% | -$25.01M-1.3% | ||
| -$27.09M-1.8% | -$26.61M-2.2% | -$26.03M-1.9% | -$25.54M-7.5% | -$23.75M-1.1% | ||
| -$0.40+7.0% | -$0.43+4.4% | -$0.450.0% | -$0.45-4.7% | -$0.43+2.3% | ||
| -$0.40+7.0% | -$0.43+4.4% | -$0.450.0% | -$0.45-4.7% | -$0.43+2.3% | ||
| 262.6M+9.2% | 240.6M+3.2% | 233.2M+2.0% | 228.7M+1.9% | 224.5M+3.2% | ||
| 262.6M+9.2% | 240.6M+3.2% | 233.2M+2.0% | 228.7M+1.9% | 224.5M+3.2% | ||
| —— | —— | —— | —— | —— | ||
| -$27.81M-0.9% | -$27.55M-1.3% | -$27.2M-1.6% | -$26.79M-7.1% | -$25.01M-1.3% | ||
| -$27.36M-0.9% | -$27.13M-1.2% | -$26.81M-1.6% | -$26.38M-7.2% | -$24.6M-1.3% | ||
| -$27.36M-0.9% | -$27.13M-1.2% | -$26.81M-1.6% | -$26.38M-7.2% | -$24.6M-1.3% | ||
| -$27.81M-0.9% | -$27.55M-1.3% | -$27.2M-1.6% | -$26.79M-7.1% | -$25.01M-1.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Vivani Medical profitable?
- Vivani Medical is not currently profitable: it reported a net loss of $27.1M over the trailing twelve months, a -994.1% net margin.
- What are Vivani Medical's profit margins?
- Gross margin is 36.3% and operating margin is -1004.9%, with a -994.1% net margin.
- What is Vivani Medical's earnings per share?
- Vivani Medical's diluted EPS over the trailing twelve months is $-0.40.
- Where does Vivani Medical's income statement data come from?
- Every line is extracted from Vivani Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.